VAXCYTE, INC. Operating Lease, Liability, Noncurrent
VAXCYTE, INC. (PCVX) had Operating Lease, Liability, Noncurrent of $108.94 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability, Noncurrent $108.94M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $110.21M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $111.46M; Operating Lease, Liability, Noncurrent as first filed $111.36M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $78.67M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $108.94M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $110.21M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $111.46M 10-Q · filed 2026-08-05 | $111.36M 10-K · filed 2026-02-24 |
| 2025-09-30 | $78.67M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $79.54M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $81.08M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $65.22M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $18.32M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $18.29M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $20.22M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $22.11M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $7.78M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $9.22M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $10.64M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $12.03M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $13.36M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $14.56M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $15.83M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $11.51M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $553.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $225.00K 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $295.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |